# Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dea-temporary-placement-schedule-i-n-desethyl-isotonitazene/ > **Published:** 2026-03-08T19:45:48-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:26:08-04:00 > **Clinical Summary:** Learn about DEA temporary placement Schedule I for N-Desethyl Isotonitazene, addressing emerging synthetic opioids with no medical use. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Regulations.gov PolicySafetyResearch Clinical Summary The Drug Enforcement Administration has temporarily placed two synthetic opioid analogues, N-desethyl isotonitazene and N-piperidinyl etonitazene, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act due to their emergence as drugs of abuse with no recognized medical use. This regulatory action reflects ongoing efforts to address the proliferation of novel synthetic opioids that circumvent existing controlled substance laws and contribute to overdose deaths. While these specific compounds are not cannabis-related, the scheduling mechanism demonstrates the broader [regulatory framework](https://cedclinic.com/tennessee-cannabis-patient-access-legislative-updates/) that also governs cannabinoid products, including delta-8 THC and other emerging cannabinoid derivatives that exploit legal loopholes. Clinicians should be aware that similar temporary scheduling actions may affect cannabis-derived or cannabis-adjacent compounds, potentially altering the legal status of products patients may be using or considering. The takeaway for [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) is to stay informed about DEA scheduling updates and counsel patients that legal availability does not guarantee safety or clinical efficacy for any controlled or scheduled substance. Clinical Perspective The DEA’s temporary scheduling of N-desethyl isotonitazene and N-piperidinyl etonitazene as Schedule I substances reflects ongoing efforts to control novel synthetic opioids that are appearing in illicit drug supplies and contributing to overdose deaths. These isotonitazene analogs represent a class of emerging synthetic opioids that can evade existing scheduling mechanisms through chemical modification, complicating both law enforcement and clinical toxicology efforts. Clinicians should be aware that patients presenting with opioid overdose symptoms may be exposed to these novel agents, which may not be detected on standard toxicology screens and could have variable clinical presentations and treatment responses compared to traditional opioids. The temporary scheduling buys time for comprehensive evaluation, though it does not directly address supply-side issues or the underlying drivers of synthetic opioid proliferation in communities. Providers managing opioid use disorder or acute overd 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Temporary+Placement+of+N-Desethyl+Isotonitazene+and+N-Piperidiny...+%40drcaplan&url=https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2023-0147-0003) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2023-0147-0003) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Temporary+Placement+of+N-Desethyl+Isotonitazene+and+N-Piperidiny...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2023-0147-0003) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.regulations.gov/document/DEA-2023-0147-0003](https://www.regulations.gov/document/DEA-2023-0147-0003) Further Reading Evidence Watch[`Cannabinoid Clinical Trials: CBD Cortical Excitability Study`](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Research Digest[Daily Digest 2026-03-07](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I](https://cedclinic.com/synthetic-opioids-schedule-i-placement-butonitazene-flunitazene/) Explore the DEA's scheduling actions on other synthetic opioids similar to N-Desethyl Isotonitazene and their clinical implications. [Read More](https://cedclinic.com/synthetic-opioids-schedule-i-placement-butonitazene-flunitazene/) [Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I](https://cedclinic.com/schedules-controlled-substances-placement-schedule-i/) Detailed review of DEA scheduling of novel synthetic opioids related to N-Desethyl Isotonitazene and their regulatory status. [Learn More](https://cedclinic.com/schedules-controlled-substances-placement-schedule-i/) [Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) Understand the broader context of DEA scheduling actions including [synthetic cannabinoids](https://cedclinic.com/synthetic-cannabinoid-parkinsons-trial-ser-252-funding/) alongside synthetic opioids. [Explore](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).